Potassium-Sparing Diuretics

Key Points

• Potassium-sparing diuretics increase sodium/water excretion while reducing potassium and hydrogen ion loss.
• They are weaker and slower-onset diuretics (effect can be delayed up to about 3 days) and are often combined with loop/thiazide diuretics to prevent hypokalemia.
• Major agents include spironolactone, eplerenone, amiloride, and triamterene.
• Priority risk is hyperkalemia, which can precipitate lethal dysrhythmias and cardiac arrest.
• Contraindications include anuria, hyperkalemia, and significant renal insufficiency.

Mechanism and Therapeutic Role

These agents act in connecting/collecting nephron segments by blocking sodium transport and/or mineralocorticoid (aldosterone) receptor signaling. Compared with loop and thiazide classes, natriuretic effect is milder but potassium retention is greater.

Spironolactone has major cardiovascular value in selected heart-failure pathways and is frequently used in resistant-hypertension or hyperaldosteronism contexts.

Drug Snapshot

Drug	Typical Adult Use Pattern	High-Yield RN Safety Points
Spironolactone	HF 25-50 mg daily; hypertension/edema/hyperaldosteronism dose ranges vary; in feminizing regimens often 100-200 mg/day PO (up to 400 mg/day by protocol)	Monitor potassium and renal function closely; endocrine effects (gynecomastia, libido/menstrual changes); review transgender antiandrogen use goals
Eplerenone	Post-MI HF and hypertension titration pathways	Potassium-based dose adjustment is essential
Amiloride	CHF or HTN pathways	Often combined with other diuretics; monitor hyperkalemia risk
Triamterene	Edema/HTN pathways	Potassium-retaining profile with additional magnesium-loss effects

Nursing Assessment

NCLEX Focus

Hyperkalemia screening is the first safety gate before each dose in high-risk clients.

• Assess baseline and trend BP, heart rate, edema burden, and fluid-balance response.
• Monitor serum potassium, sodium, renal function markers, and ECG rhythm changes during therapy.
• Screen for contraindications: anuria, hyperkalemia, renal insufficiency, severe hypovolemia, and Addison disease.
• Review comorbid risks requiring higher vigilance (older age, diabetes, gout, renal impairment).
• Assess for interaction burden with potassium supplements/salt substitutes, ACE inhibitors, ARBs, NSAIDs, lithium, digoxin, and related agents.
• In transgender feminizing therapy pathways, assess baseline and follow-up potassium and renal function before/after dose changes.

Nursing Interventions and Teaching

• Use potassium-sparing drugs as prescribed in combination regimens to reduce loop/thiazide-induced potassium loss.
• Reinforce daily weight and edema monitoring; escalate gains greater than about 2 lb/day or 5 lb/week.
• Reinforce follow-up labs and ECG checks for early detection of electrolyte-triggered arrhythmia risk.
• Teach clients to avoid unsupervised potassium supplements and potassium-based salt substitutes.
• Review hidden dietary potassium contributors (for example dried fruits, bananas, and dark green/yellow vegetables) when hyperkalemia risk is elevated.
• Reinforce taking medication consistently with respect to food (same with-food or without-food pattern).
• Reinforce avoiding unsupervised NSAID use because it can worsen hyperkalemia/renal-risk profiles.
• Instruct clients to report weakness, palpitations, bradycardia, syncope, or severe fatigue immediately.
• Counsel regarding spironolactone endocrine effects and when to notify the prescriber.

Hyperkalemia Emergency Risk

Potassium-sparing diuretics can cause severe hyperkalemia; untreated cases may progress to ventricular arrhythmia or cardiac arrest.

Interaction Cluster

Concomitant ACE inhibitors, ARBs, NSAIDs, lithium, or potassium supplements significantly increase toxicity risk and require structured monitoring.

Product Safety Warnings

High-dose spironolactone has tumor-signal warnings, and amiloride/triamterene can precipitate severe hyperkalemia, especially in renal impairment or diabetes contexts.

Clinical Judgment Application

Clinical Scenario

A client with class III heart failure is started on spironolactone and returns with muscle weakness and new ECG conduction changes.

• Recognize Cues: Potassium-sparing therapy with neuromuscular and rhythm-warning findings.
• Analyze Cues: Emerging hyperkalemia is likely and may be life-threatening.
• Prioritize Hypotheses: Highest priority is dysrhythmia risk from potassium elevation.
• Generate Solutions: Obtain urgent potassium/renal labs, medication-interaction review, and provider escalation plan.
• Take Action: Hold unsafe doses per protocol, initiate monitoring, and implement ordered potassium-lowering interventions.
• Evaluate Outcomes: Potassium normalizes, ECG stabilizes, and regimen is safely adjusted.

Related Concepts

• diuretics - Class-level framework for loop, thiazide, potassium-sparing, and osmotic pathways.
• loop-diuretics - Common combination partner to reduce potassium-wasting effects.
• heart-failure - Spironolactone/eplerenone pathways in selected HF populations.
• potassium-balance-disorders - Hyperkalemia recognition and escalation priorities.